Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Letrozole (Primary) ; Maveropepimut-S (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Proof of concept
- 24 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 9 Nov 2023.
- 09 Aug 2023 Planned End Date changed from 1 Jun 2026 to 1 Sep 2026.
- 09 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.